Association Between Programmed Death-Ligand 1 Expression and Clinicopathological Characteristics, Structural Recurrence, and Biochemical Recurrence/Persistent Disease in Medullary Thyroid Carcinoma-Reference-Cited by-同舟云学术

Association Between Programmed Death-Ligand 1 Expression and Clinicopathological Characteristics, Structural Recurrence, and Biochemical Recurrence/Persistent Disease in Medullary Thyroid Carcinoma

Published:2019-09-01 Issue:9 Volume:29 Page:1269-1278
ISSN:1050-7256
Container-title:Thyroid
language:en
Short-container-title:Thyroid

Author:

Shi Xiao¹²,Yu Peng-Cheng¹²,Lei Bo-Wen¹²,Li Cui-Wei¹²,Zhang Yan²³,Tan Li-Cheng¹²,Shi Rong-Liang¹²,Wang Jie⁴,Ma Ben¹²,Xu Wei-Bo¹²,Wang Xiao¹²,Hu Jia-Qian¹²,Huang Nai-Si¹²,Wei Wen-Jun¹²,Wang Yu¹²,Chen Tong-Zhen²³,Wang Yu-Long¹²,Ji Qing-Hai¹²

Affiliation:

1. Department of Head and Neck Surgery, Fudan University Shanghai Cancer Center, Shanghai, People's Republic of China.

2. Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, People's Republic of China.

3. Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, People's Republic of China.

4. Department of General Surgery, Fudan University Zhongshan Hospital, Shanghai, People's Republic of China.

Publisher

Mary Ann Liebert Inc

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism

Link

https://www.liebertpub.com/doi/pdf/10.1089/thy.2019.0079

Reference49 articles.

1. MEDULLARY (SOLID) CARCINOMA OF THE THYROID—A CLINICOPATHOLOGIC ENTITY*

2. Medullary Thyroid Carcinoma: a 25-Year Perspective

3. Prognostic factors for thyroid carcinoma

4. Trends in the presentation, treatment, and survival of patients with medullary thyroid cancer over the past 30 years

5. Revised American Thyroid Association Guidelines for the Management of Medullary Thyroid Carcinoma

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immune microenvironment in papillary thyroid carcinoma: roles of immune cells and checkpoints in disease progression and therapeutic implications;Frontiers in Immunology;2024-09-03

2. Theranostics of Thyroid Cancer;Seminars in Nuclear Medicine;2024-07

3. Combination Targeted Therapy with Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers;Clinical Cancer Research;2024-06-26

4. Medullary Thyroid Cancer: Molecular Drivers and Immune Cellular Milieu of the Tumour Microenvironment—Implications for Systemic Treatment;Cancers;2024-06-22

5. Tumor microenvironment in thyroid cancer: Immune cells, patterns, and novel treatments;Head & Neck;2024-02-21